
UPDATED Dewpoint nabs ex-Sanofi CEO Brandicourt and Bayer VC chief Eckhardt for board
Bayer-partnered Dewpoint Therapeutics is adding a pair of big-name pharma vets as it looks to make drugs targeting biomolecular condensates a reality.
The Boston biotech will add former Sanofi CEO Olivier Brandicourt and the head of Bayer’s venture arm, Jürgen Eckhardt, to its board. Though both MDs, the pair has held long careers on the business side of the industry, which is where their insight will be needed most, said Dewpoint CEO Amir Nashat.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.